Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
EyePoint Pharmaceuticals's peak revenue was $46.0M in 2023. The peak quarterly revenue was $15.2M in 2023(q3).
EyePoint Pharmaceuticals's revenue increased from $381.7k in 2004 to $43.3M currently. That's a 11,237.54% change in annual revenue.
| Fiscal year / year | EyePoint Pharmaceuticals revenue |
|---|---|
| 2009 | $12.2M |
| 2010 | $23.1M |
| 2011 | $5.0M |
| 2012 | $3.5M |
| 2013 | $2.1M |
| 2014 | $3.5M |
| 2015 | $26.6M |
| 2016 | $1.6M |
| 2017 | $7.5M |
| 2018 | $3.0M |
| 2019 | $20.4M |
| 2020 | $34.4M |
| 2021 | $36.9M |
| 2022 | $41.4M |
| 2023 | $46.0M |
| 2024 | $43.3M |
How accurately did EyePoint Pharmaceuticals' revenue projections match actual performance?
EyePoint Pharmaceuticals saw the greatest revenue growth in 2006, when revenue increased by 124,869.84%.
EyePoint Pharmaceuticals had the lowest revenue growth in 2005, when revenue changed by -99.78%.
| Year | EyePoint Pharmaceuticals growth |
|---|---|
| 2009 | 250%↑ |
| 2010 | 90%↑ |
| 2011 | -78%↓ |
| 2012 | -29%↓ |
| 2013 | -39%↓ |
| 2014 | 62%↑ |
| 2015 | 665%↑ |
| 2016 | -94%↓ |
| 2017 | 365%↑ |
| 2018 | -61%↓ |
| 2019 | 588%↑ |
| 2020 | 69%↑ |
| 2021 | 7%↑ |
| 2022 | 12%↑ |
| 2023 | 11%↑ |
| 2024 | -6%↓ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | - | - | - | $7.1M |
| 2021 | $7.3M | $9.0M | $9.1M | $11.5M |
| 2022 | $9.3M | $11.6M | $10.0M | $10.5M |
| 2023 | $7.7M | $9.1M | $15.2M | $14.0M |
| 2024 | $11.7M | $9.5M | $10.5M | $11.6M |
Do you work at EyePoint Pharmaceuticals?
Did EyePoint Pharmaceuticals meet its revenue projections?
| CEO | Paul Ashton |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 100 |
| Date Founded | 1987 |
| Headquarters | Watertown Town, Massachusetts |
| Revenue | $43.3M |
| Net Income | -$102,254,000 |
| Gross Proft | $39.6M (2024) |
| PE Ratio | -1.29 |
| Tax Rate | -0.0% |
| Market Capitalization | $168.8M |
| Total Assets | $180,356,000 |
| Ticker | EYPT |
EyePoint Pharmaceuticals received early financing of $40.0M on 2012-07-18.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $40M | 07/2012 |
| Post Ipo Equity | $10.8M | 07/2013 |
| Post Ipo Equity | $7M | 03/2014 |
| Post Ipo Equity | $29M | 10/2018 |
| Debt Financing | $60M | 02/2019 |
| Post Ipo Equity | $15.7M | 01/2021 |
| Post Ipo Equity | $115M | 02/2021 |
| Investors | Security type |
|---|---|
| RA Capital Management | Post Ipo Equity |
| Rosalind Advisors | Post Ipo Equity |
| EW Healthcare Partners | Post Ipo Equity |
| CRG | Debt Financing |
| Ocumension Therapeutics | Post Ipo Equity |
Zippia gives an in-depth look into the details of EyePoint Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about EyePoint Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at EyePoint Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by EyePoint Pharmaceuticals. The data presented on this page does not represent the view of EyePoint Pharmaceuticals and its employees or that of Zippia.
EyePoint Pharmaceuticals may also be known as or be related to EYEPOINT PHARMACEUTICALS, INC., EyePoint Pharmaceuticals, EyePoint Pharmaceuticals Inc and EyePoint Pharmaceuticals, Inc.